SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


[X]

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

 

 

[  ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________  to __________________


Commission File Number: 000-54905


Cantabio Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)


Delaware

000-54905

99-0373067

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

 

 

1250 Oakmead Pkwy

Sunnyvale, California

 

94085

(Address of principal executive offices)

 

(Zip Code)


844-200-2826

Registrant’s telephone number, including area code


N/A

(Former name or former address, if changed since last report)


Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  [X] Yes  [  ] No


Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  [X] Yes  [  ] No


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer

[  ]

 

Accelerated filer

[  ]

Non-accelerated filer

[X]

 

Smaller reporting company

[X]

 

 

 

Emerging Growth Company

[  ]


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  [  ] Yes  [X] No


As of November 9, 2018, there were 81,950,977 shares of the issuer’s common stock issued and outstanding.





CANTABIO PHARMACEUTICALS, INC


FORM 10-Q


TABLE OF CONTENTS


PART I - FINANCIAL INFORMATION

 

 

 

Item 1.

Condensed Consolidated Interim Financial Statements (Unaudited)

2

 

 

 

 

Condensed Consolidated Balance Sheets as of September 30, 2018 and March 31, 2017

2

 

 

 

 

Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2018 and 2017

3

 

 

 

 

Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2018 and 2017

4

 

 

 

 

Notes to Condensed Consolidated Financial Statements

5

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

12

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

13

 

 

 

Item 4.

Controls and Procedures

14

 

 

PART II - OTHER INFORMATION

 

 

 

Item 1.

Legal Proceedings

15

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

15

 

 

 

Item 3.

Defaults Upon Senior Securities

15

 

 

 

Item 4.

Mine Safety Disclosures

15

 

 

 

Item 5.

Other Information

15

 

 

 

Item 6.

Exhibits

15

 

 

 

SIGNATURES

16












2




PART I - FINANCIAL INFORMATION


ITEM 1. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)


CANTABIO PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)



 

 

September 30,

2018

 

March 31,

2018

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

  Cash

 

$

21,527

 

$

109,426

Total Current Assets

 

 

21,527

 

 

109,426

 

 

 

 

 

 

 

TOTAL ASSETS

 

$

21,527

 

$

109,426

 

 

 

 

 

 

 

LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

  Accounts payable and accrued expenses

 

 

641,354

 

 

606,751

  Accrued technology access fee

 

 

162,217

 

 

171,105

  Secured convertible debentures

 

 

1,479,690

 

 

947,160

  Convertible debt related party

 

 

161,148

 

 

257,614

Total Current Liabilities

 

 

2,444,409

 

 

1,982,630

 

 

 

 

 

 

 

TOTAL LIABILITIES

 

$

2,444,409

 

$

1,982,630

 

 

 

 

 

 

 

Stockholders' Equity (Deficit)

 

 

 

 

 

 

  Common stock, $0.001 par value, (250,000,000 shares

    authorized, 78.5 million and 51.9 million shares issued

    and outstanding as of September 30, 2018 and March

    31, 2018, respectively)

 

 

78,537

 

 

51,857

  Stock subscriptions

 

 

1,060,000

 

 

1,060,000

  Additional paid in capital

 

 

1,593,884

 

 

1,134,763

  Accumulated deficit

 

 

(5,155,303)

 

 

(4,119,824)

Total Stockholders' Equity (Deficit)

 

 

(2,422,882)

 

 

(1,873,204)

 

 

 

 

 

 

 

TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)

 

$

21,527

 

$

109,426






The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.



3




CANTABIO PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)



 

 

For the three months ended

September 30,

 

For the six months ended

September 30,

 

 

2018

 

2017

 

2018

 

2017

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

  Research & development

 

$

79,003

 

$

98,904

 

$

190,223

 

$

196,096

  General & administrative

 

 

155,128

 

 

177,435

 

 

279,780

 

 

368,169

Total operating expenses

 

 

234,131

 

 

276,339

 

 

470,003

 

 

564,265

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(234,131)

 

 

(276,339)

 

 

(470,003)

 

 

(564,265)

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

  Interest expense

 

 

(288,693)

 

 

(112,952)

 

 

(637,684)

 

 

(187,423)

  Change in fair value of embedded

    derivatives, including modification

    accounting

 

 

2,000

 

 

44,000

 

 

120,000

 

 

54,000

  Loss on extinguishment of debt,

    related party

 

 

(91,621)

 

 

-

 

 

(91,621)

 

 

-

Gain on extinguishment of debentures

 

 

43,829

 

 

-

 

 

43,829

 

 

-

Total Other Income & (Expenses)

 

 

(334,485)

 

 

(68,952)

 

 

(565,476)

 

 

(133,423)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(568,616)

 

$

(345,291)

 

$

(1,035,479)

 

$

(697,688)

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted Loss per share

 

$

(0.01)

 

$

(0.01)

 

$

(0.02)

 

$

(0.03)

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common

  shares outstanding

 

 

58,430,000

 

 

27,284,000

 

 

55,745,000

 

 

27,145,000












The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.



4




CANTABIO PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)



 

 

Six Months Ended

September 30,

 

 

2018

 

2017

 

 

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

Net loss

 

$

(1,035,479)

 

$

(697,688)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

  Loss on extinguishment of debt related party

 

 

91,621

 

 

-

  Gain on extinguishment of debentures

 

 

(43,829)

 

 

-

  Loss on extinguishment of obligation

 

 

17,500

 

 

-

  Amortization of debt discount

 

 

594,621

 

 

156,406

  Change in fair value of embedded derivative

 

 

(120,000)

 

 

(54,000)

  Share based compensation for services

 

 

10,000

 

 

39,549

Changes in operating assets and liabilities:

 

 

 

 

 

 

  Accounts payable and accrued expenses

 

 

104,601

 

 

232,564

  Accrued technology access fee

 

 

(8,888)

 

 

17,688

  Accrued debenture interest

 

 

36,954

 

 

21,153

  Prepaid Expenses

 

 

-

 

 

1,248

Net cash used in operating activities

 

 

(352,899)

 

 

(283,080)

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

  Proceeds from issuance of convertible debt related party, net of

    issuance cost

 

 

265,000

 

 

175,000

  Proceeds from issuance of convertible debenture, net of

    issuance cost

 

 

-

 

 

127,000

Net cash provided by financing activities

 

 

265,000

 

 

302,000

 

 

 

 

 

 

 

Net increase (decrease) in cash

 

 

(87,899)

 

 

18,920

 

 

 

 

 

 

 

Cash at beginning of period

 

 

109,426

 

 

32,275

Cash at end of period

 

$

21,527

 

$

51,195

 

 

 

 

 

 

 

Schedule of non-cash financing activities

 

 

 

 

 

 

  Recognition of beneficial conversion feature associated with

    convertible debentures

 

$

-

 

$

35,000

  Conversion of secured convertible debenture

 

$

118,785

 

$

-

  Conversion of convertible debt related party

 

$

269,517

 

$

-

  Issuance of shares for settlement of accounts payable

 

$

70,000

 

$

27,178







The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.



5




CANTABIO PHARMACEUTICALS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)


NOTE 1 - ORGANIZATION AND DESCRIPTION OF THE BUSINESS


Cantabio Pharmaceuticals Inc. (the “Company” or “Cantabio”) is a preclinical stage biotechnology company focusing on commercializing novel therapies and the intellectual property generated from research and development activities for Parkinson’s disease (PD) and Alzheimer’s disease (AD). The Company’s strategy involves integration of therapeutic focus, the targeting of family biophysics, drug discovery technology and expertise into an innovative drug discovery approach, which synergizes to identify and develop small molecule pharmacological chaperones for clinical trials. In addition, the Company’s research efforts concentrate on the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins with display loss of function during disease conditions.


NOTE 2 - GOING CONCERN


As of September 30, 2018, the Company had a working capital deficit and continues to have losses from operations due to its research and development activities.


The Company typically raises capital which it spends on maintaining its research and corporate operations. At this early stage in the life of the Company funding is often short term in nature. While the Company has been proficient in raising funds in the past the short-term nature of these funding cycles raises substantial doubt about the Company's ability to continue as a going concern within one year from the date of this filing.


Management is addressing going concern risk by seeking new sources of capital and is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to meet future working capital requirements. Furthermore, strategic partnerships, most likely with larger pharmaceutical industry companies, will be needed to continue to fund research and development costs as our projects expand. These measures, if successful, may contribute to reduce the risk of going concern uncertainties for the Company for at least twelve months from issuance of these condensed consolidated financial statements.


The ability of the Company to continue as a going concern is dependent upon its ability to raise additional capital and achieve profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.


NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES


Interim Reporting

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (“SEC”) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance. Operating results for the three months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending March 31, 2019. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended March 31, 2018.




6




Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.


Earnings (Loss) per Share

The Company calculates earnings per share using basic net income (loss) per common share be computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period. The Company does not compute diluted earnings per share because to do so would be anti-dilutive.


Potentially dilutive securities


 

 

September 30,

 

September 30,

 

 

2018

 

2017

Convertible debentures (Note 6)

 

59,045,000

 

11,331,000

Convertible debt related party (Note 7)

 

7,843,000

 

5,450,000

Stock subscriptions

 

530,000

 

530,000


Recent Accounting Standards


Fiscal 2019 Accounting Standards Adoptions


In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. This new standard became effective for the Company on April 1, 2018. The new standard does not have a material impact on our financial statements.


Recently Issued Accounting Standards


In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 increases the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Certain qualitative and quantitative disclosures are required, as well as a retrospective recognition and measurement of impacted leases. The new ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of this new standard and does not expect it to have a material impact on our financial statements.


In June 2018, the FASB issued Accounting Standards Update (ASU) 2018-07 intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments.  Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. This ASU expands the scope of Topic 718, Compensation-Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity-Equity-Based Payments to Nonemployees.




7



The amendments in this ASU are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other companies, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company's adoption date of Topic 606, Revenue from Contracts with Customers.  The Company is currently evaluating the impact of this new standard and does not expect it to have a material impact on our financial statements.


SEC Disclosure Update and Simplification


In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements.


NOTE 4 - RELATED PARTY TRANSACTIONS


There have been no changes to the Company’s related party consulting arrangements as they have been disclosed in our most recently filed form 10K.


Costs incurred associated with related party transactions included in general and administrative in the statement of operations are as follows:


 

 

For the six months ended

September 30,

 

 

2018

 

2017

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

   Toth and Associates LTD

 

$

87,000

 

$

80,000

   Capro LTD

 

 

48,000

 

 

66,000

   Eden Professional LTD

 

 

45,000

 

 

42,000

   Max Zhu Consulting

 

 

6,000

 

 

12,000

 

 

 

 

 

 

 

Total related party transactions

 

$

186,000

 

$

200,000


Accounts payable and accrued expenses includes amounts payable to related parties of $0.3 and $0.6 million for the period ended September 30, 2018 and March 31, 2018, respectively.


NOTE 5 - CONVERTIBLE DEBENTURES AS AMENDED


New issuance

On June 5, 2018 the Company entered into a new securities purchase agreement with an accredited investor to place Convertible Debentures (as amended the “Debentures”) in the aggregate principal amount of up to $300,000 net of issuance costs of $35,000 (the “Transaction”). The Debentures bear interest at the rate of 5% per annum with a maturity date of June 5, 2019, as may be extended at the option of the note holder.  In addition, the Company must pay to the holder an annual fee equal to 7% of the amount of the Debentures to assist in their monitoring costs for the Debentures. The net proceeds of the financing were used for general corporate matters and for other expenses. The Debentures may be converted at any time on or prior to maturity at the lower of $0.05 or 93% of the average of the three lowest daily volume weighted average price (“VWAP”) during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the Debenture and the conversion price is never lower than a stated floor price.




8




Amendment

At the same time all previous debentures were amended to align them with the new agreement.  All the Debentures may be converted at any time on or prior to maturity at the lower of $0.05 (rather than $0.10 as previously) or 93% of the average of the three lowest daily volume weighted average price (“VWAP”) during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the Debenture and the conversion price is never lower than a stated floor price.  The Company accounted for the amendment as a debt modification which resulted in $76,000 impact that was recorded in the change in fair value of embedded derivatives in the Company’s statements of operations.


Embedded Derivative


Embedded Derivatives - Monthly Payment Provision

The monthly payment provision within the Debentures is a contingent put option that is required to be separately measured at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statements of Operations. The Company estimated the fair value of the monthly payment provision, as of the issuance date and September 30, 2018 using probability analysis of the occurrence of a Triggering Date applied to the discounted maximum redemption premium for any given payment.


The probability analysis utilized in calculating the embedded derivative at September 30, 2018 and March 31, 2018 was calculated using the following key inputs:


Monthly Payment Provision


 

September 30, 2018

 

March 31, 2018

Stock price

$0.017

 

$0.06

Probability of Triggering Date

100%

 

100%

Volatility

300%

 

300%

Risk-free rate

1%

 

1%

Discount rate

0%

 

0%


Due to the Company’s sequencing policy the Company recorded an embedded derivative associated with the conversion feature.  The following are the inputs associated with the conversion feature.


Conversion Feature


 

September 30, 2018

 

March 31, 2018

Stock price

$0.017

 

$0.06

Exercise price

$0.016

 

$0.06

Volatility

400%

 

300%

Contractual term

0.14 - 0.68 year

 

1 year

Risk-free rate

1%

 

1%

Discount rate

0%

 

0%


The fair value estimate of the embedded derivatives is a Level 3 measurement. The roll-forward of the Level 3 fair value measurement, for the six months ended September 30, 2018, is as follows:


Balance at

March 31, 2018

 

Issuance of

new debentures

 

Change due to

modification

 

Net realized

(gain)/loss

 

Conversion

 

Balance at

September 30, 2018

$ 736,000

 

$ 281,000

 

$ 76,000

 

$ (200,000)

 

$ (65,000)

 

$ 828,000





9



The approximate carrying value of the Debentures, as of September 30, 2018 and March 31, 2018 is comprised of the following:


 

September 30, 2018

 

March 31, 2018

  Principal value of 5%, convertible, net of conversion

$

916,000

 

$

750,000

  Fair value of embedded derivatives

 

828,000

 

 

736,000

  Accrued interest

 

34,000

 

 

22,264

  Debt discount

 

(298,000)

 

 

(561,104)

Carrying value of Secured Convertible Debenture Note

$

1,480,000

 

$

947,160


As of September 30, 2018, the estimated aggregate fair value of outstanding convertible notes payable is approximately $1.5 million. The fair value estimate is based on the estimated option value of the conversion terms. The estimated fair value represents a Level 3 measurement.


Secured Convertible Debenture Conversions

During the six months ended September 30, 2018, holders of approximately $0.16 million in principal amount and accrued interest with respect to Secured Convertible Debentures exercised the conversion option and converted into 7.1 million shares of common stock. The fair market value of the shares issued of $0.12 million was less than the net carrying value of the convertible notes by $0.04 million and a gain on extinguishment was recorded.


Events of Default or Financial covenants

The Company is in compliance with all terms associated with the convertible note.


NOTE 6 - CONVERTIBLE DEBT RELATED PARTY


Overview

The carrying value of the Notes, as of September 30, 2018 and March 31, 2018 is comprised of the following:


 

September 30, 2018

 

March 31, 2018

  Principal value of 5%, convertible, net of conversion

$

120,000

 

$

220,000

  Fair value of embedded derivatives

 

95,000

 

 

156,000

  Accrued interest

 

4,800

 

 

15,204

  Debt discount

 

(58,000)

 

 

(133,590)

Carrying value of Secured Convertible Debenture Note

$

161,000

 

$

257,614


As of September 30, 2018, the estimated aggregate fair value of outstanding convertible notes payable is approximately $0.2 million. The fair value estimate is based on the estimated option value of the conversion terms. The estimated fair value represents a Level 3 measurement.


Conversions

In September 2018 the holder converted $100,000 of principal and $25,789 of interest into approximately 10.7 million shares of common stock. The fair market value of the shares issued of $0.3 million exceeded the net carrying value of the convertible notes by $0.1 million and a loss on extinguishment was recorded.


Embedded features

The analysis utilized in calculating the embedded derivative at September 30, 2018 and March 31, 2018 was calculated using the following key inputs:


 

September 30, 2018

 

March 31, 2018

Stock price

$0.017

 

$0.06

Contractual term

0.27 years

 

0.1 - 1.0 years

Volatility

400%

 

300%

Risk-free rate

1%

 

1%




10




The fair value estimate of the embedded derivative is a Level 3 measurement. The roll-forward of the Level 3 fair value measurement, for the six months ended September 30, 2018, is as follows:
 

Balance at

March 31, 2018

 

Conversion

 

Net unrealized

(gain)/loss

 

Balance at

September 30, 2018

$ 156,000

 

$ (65,000)

 

$ 4,000

 

$ 95,000


Technical default

The remaining note which was due in July 2018 is in technical default, although the obligation has not been called by the lender.


NOTE 7 - CAPITAL STOCK


Issuance of shares for consulting services.

During the six months ended September 30, 2018 the Company issued approximately 0.4 million shares with a fair value of approximately $10,000 as compensation for services performed, and issued approximately 8.6 million shares to Directors of the company in lieu of $70,000 of unpaid fees.


NOTE 8 - SUBSEQUENT EVENTS


The Company issued a convertible loan note to a related party for $115,000.  The loan matures in 6 months, and earns interest at 24% before maturity and 29% thereafter, with conversion terms substantially similar to those already existing


A holder of convertible debentures converted approximately $0.4 million of principal and interest into approximately 3.4 million shares of common stock.



























11




ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this report.


This Quarterly Report contains forward-looking statements about our business, financial condition and prospects that reflect management’s assumptions and beliefs based on information currently available.  The expectations indicated by such forward-looking statements might not be realized.  If any of our management’s assumptions should prove incorrect, or if any of the risks and uncertainties underlying such expectations should materialize, our actual results may differ materially from those indicated by the forward-looking statements.


The key factors that are not within our control and that may have a direct bearing on operating results include, but are not limited to, managements’ ability to raise capital in the future, the retention of key employees and changes in the regulation of our industry.  There may be other risks and circumstances that management may be unable to predict.


When used in this Quarterly Report, words such as, "believes," "expects," "intends," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions.


As of September 30, 2018, we had approximately $22,000 cash in the bank. This amount will not satisfy our cash requirements for the next twelve months. We plan to satisfy our future cash requirements by additional equity financing. This will likely be in the form of private placements of common stock. Additional equity financing may not be available to us on acceptable terms or at all, and thus we could fail to satisfy our future cash requirements.


If we are unsuccessful in raising the additional proceeds through a private placement offering, we will then have to seek capital from other sources such as debt financing, which may not be available to us. However, if such financing were available, we would likely have to pay additional costs associated with high risk loans and be subject to an above market interest rate. At such time these funds are required, management would evaluate the terms of such debt financing and determine whether the business could manage the debt load. If we cannot raise additional proceeds via a private placement of our common stock or secure debt financing we would be required to cease as a business. As a result, investors in our common stock would lose all of their investment.


Results of Operations for the three months ended September 30, 2018, as compared to the three months ended September 30, 2017.


Our operating expenses decreased to $234,131 for the three months ended September 30, 2018 from $276,339 in the three months ended September 30, 2017. The R&D spend of $79,003 in the three months to September 30, 2018 compares with $98,904 on R&D in the same period in 2017, due to headcount having reduced between the two periods. There was a decrease in General and Administrative expenses to $155,128 in the three months to September 30, 2018 from $177,435 in the three months to September 30, 2017. The decrease was largely driven by decreased legal and professional fees related to fundraising activities.


We generated Other Expense in the three months ended September 30, 2018 of $334,485 made up of $288,693 of interest expense, the overwhelming majority of which relates to amortization of debt discount connected with convertible instruments, a $2,000 gain in fair value of an embedded derivative, and a net $47,792 loss on extinguishment of debt and debentures. Other Expense for the same period of 2017 was $68,952, made up of $112,952 of interest expense, partially offset by a $44,000 gain in fair value of an embedded derivative.





12




Results of Operations for the six months ended September 30, 2018, as compared to the six months ended September 30, 2017.


Our operating expenses decreased to $470,003 for the six months ended September 30, 2018 from $564,265 in the six months ended September 30, 2017. R&D spend of $190,223 in the six months to September 30, 2018, compared to $196,096 in the same period in 2017 driven by lower staff costs in 2017 partially offset by higher third-party R&D costs. There was a decrease in General and Administrative expenses to $279,780 in the six months to September 30, 2018 from $368,169 in the same period in 2017 largely driven by reduction in legal and professional fees which were high in 2017 due to fundraising activities.


Other Expense in the six months ended September 30, 2018 was $565,476 made up of $637,684 of interest expense, the majority of which relates to amortization of debt discount connected with convertible instruments, and $47,792 net loss on extinguishment of debt and debentures, offset by a gain in the value of embedded derivatives of $120,000. In the six months to September 30, 2017 Other Expense was $133,423 made up of $187,423 of interest expense, offset by a gain in the value of embedded derivatives of $54,000.


Liquidity and Capital Resources


On September 30, 2018, we had approximately $22,000 in current assets, consisting entirely of cash. Our total current liabilities as of September 30, 2018, were approximately $2,444,000. Thus, we had negative working capital of approximately $2,422,000 as of September 30, 2018.


Cash Flows from Financing Activities. During the six months ended September 30, 2018, financing activities provided $265,000 from a convertible debenture facility. This compares to approximately $127,000 from a convertible debenture facility and approximately $175,000 from related party convertible notes in the same period in 2017.


The Company typically raises capital which it spends on maintaining its research and corporate operations.  At this early stage in the life of the Company, funding is often short term in nature. While the Company has been proficient in raising funds in the past, the short-term nature of these funding cycles raises substantial risk around the Company's ability to continue as a going concern.


Management is addressing going concern risk by seeking new sources of capital and is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to meet future working capital requirements.  Furthermore, strategic partnerships, most likely with larger pharmaceutical industry companies, will be needed to continue to fund research and development costs as our projects expand. These measures, if successful, may contribute to reduce the risk of going concern uncertainties for the Company beyond the next twelve months.


Our financial statements indicate there is substantial doubt about our ability to continue as a going concern as this would depend upon our ability to obtain ongoing financing and ultimately to generate sufficient cash flow to meet our obligations on a timely basis. Our plans and efforts to achieve the above steps might not be successful, which raises substantial doubt about the Company's ability to continue as a going concern within one year from the date of this filing.


OFF BALANCE SHEET ARRANGEMENTS


The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK


Not applicable.




13




ITEM 4. CONTROLS AND PROCEDURES


A set of disclosure controls and procedures designed to ensure that information required to be disclosed by us in the reports filed under the Securities Exchange Act, is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms is required to be maintained by management. Disclosure controls should be designed with the objective of ensuring that this information is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.  Management has not designed and currently does not maintain a designed set of disclosure controls and procedures.


We have not evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. As a result, management has concluded that our disclosure controls and procedures were not effective for the quarter ended September 30, 2018, due to the following:


1.

Failure to design and maintain a set of disclosure and control procedures


2.

Lack of segregation of duties as a result of limited personnel.


3.

Lack of Functioning Audit Committee - We do not have an Audit Committee, our board of directors currently acts as our Audit Committee.  We do not have an independent director.
































14




PART II - OTHER INFORMATION


ITEM 1. LEGAL PROCEEDINGS.


None.


ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.


On September 11, 2018, a holder of a convertible debenture converted $34,329 of principal and interest on such debenture into 2,795,502 shares of our common stock at $0.01228 per share pursuant to the terms of such debenture.


On September 20, 2018, a holder of a convertible note converted $125,789 of principal and interest on such loan into 10,652,853 shares of our common stock at $0.011808 per share pursuant to the terms of such loan.


On September 20, 2018, we issued 8,578,431 shares of our common stock to our Directors in lieu of unpaid fees totalling $70,000 at a price of $0.00816.


On October 17, 2018, a holder of a convertible debenture converted $40,008 of principal and interest on such debenture into 3,413,670 shares of our common stock at $0.01172 per share pursuant to the terms of such debenture.


ITEM 3. DEFAULTS UPON SENIOR SECURITIES


None.


ITEM 4. MINE SAFETY DISCLOSURES


None


ITEM 5. OTHER INFORMATION


None.


ITEM 6. EXHIBITS


Exhibit No.

Description

31.1

Certification of Principal Executive Officer and Acting Principal Accounting Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934

31.2

Certification of Chief Financial Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934

32.1

Certification of the Principal Executive Officer and Acting Principal Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2

Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS

 XBRL Instance Document

101.SCH

 XBRL Taxonomy Extension Schema Document

101.CAL

 XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

 XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

 XBRL Taxonomy Extension Label Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document






15




SIGNATURES


In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Cantabio Pharmaceuticals Inc.


By: /s/ Gergely Toth

Gergely Toth

Its: President, Chief Executive Officer, Director (Principal Executive Officer).

November 13, 2018


By: /s/ Simon Peace

Simon Peace

Its: Chief Financial Officer, Director (Principal Accounting Officer)

November 13, 2018
































16